Research Progress on NMDA Receptor Enhancement Drugs for the Treatment of Depressive Disorder.

Major depressive disorder is a severe mental illness whose current medications often work slowly and cause side effects. The N-methyl-D-aspartate receptor (NMDAR), a type of glutamate-gated ion channel, is linked to depression based on preclinical and clinical research. The NMDAR antagonist ketamine produces rapid and lasting antidepressant effects but has psychotomimetic effects and addiction potential that limit its use. Over the past decade, evidence suggests that enhancing NMDAR function, particularly through positive allosteric modulators (PAMs), may offer antidepressant benefits with improved safety. This narrative review presents that approach as a potential novel strategy for treating depression.

Study at a glance

Abstract

Major depressive disorder (MDD) is a severe mental illness with a complex etiology. Currently, many medications employed in clinical treatment exhibit limitations such as delayed onset of action and a high incidence of adverse reactions. Therefore, there is a pressing need to develop antidepressants that exhibit enhanced efficacy and safety. The N-methyl-D-aspartate receptor (NMDAR), a distinctive glutamate-gated ion channel receptor, has been implicated in the onset and progression of depressive disorder, as evidenced by both preclinical and clinical research. The NMDAR antagonist, ketamine, exhibits rapid and sustained antidepressant effects, holding promise as a novel therapeutic approach for depressive disorder. However, its psychotomimetic impact and potential for addiction have restricted its widespread clinical application. Notably, over the past decade, studies have suggested that enhancing NMDAR functionality can produce antidepressant effects with improved safety, especially with the emergence of NMDAR-positive allosteric modulators (PAMs). We view this as a potential novel strategy for treating depression, forming the basis for the narrative review that follows.